RBC Capital analysts initiated coverage on Bristol-Myers Squibb Company PFD CONV 2 (OTC:BMYMP) with a Sector Perform rating on February 25, 2026.
Bristol-Myers Squibb Company PFD CONV 2 operates in the Healthcare sector. The stock currently trades at $1050.00 with a market capitalization of $1815.9B.
Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bristol-Myers Squibb Company PFD CONV 2.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
